EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Hydrogel formats to model potential drug interactions occurring at the subcutaneous injection site

Conor Gomes, Kate Gridley, Imogen Anastasiou, Bálint Sinkó, Randall J Mrsny

European Journal of Pharmaceutics and Biopharmaceutics · 2024-06 · 199 · 114308

DOI: 10.1016/j.ejpb.2024.114308 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Pharmaceutics and Biopharmaceutics, 2024-06. Verfasst von Conor Gomes und 4 weiteren Autor:innen. Beteiligte Einrichtung: Pion, Inc., Billerica, MA 01821, USA. Hauptthemen laut MEDLINE: Hyaluronic Acid, Hydrogels. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

We have previously developed an in vitro instrument, termed subcutaneous injection site simulator (SCISSOR), that can be used to monitor release properties of an active pharmaceutical ingredient (API) and formulation components of a medicine designed for SC injection. Initial studies to validate the SCISSOR instrument applications used a simple hyaluronic acid (HA) hydrogel to monitor early release events. We now report a type of cross-linked HA that can, when combined with HA, provide a hydrogel (HA-XR) with optical clarity and rheological properties that remain stable for at least 6 days. Incorporation of 0.05-0.1 mg/mL of collagens isolated from human fibroblasts (Col F), bovine type I collagen (Col I), chicken collagen type II (Col II), or chondroitin sulphate (CS) produced HA or HA-XR hydrogel formats with optical clarity and rheological properties comparable to HA or HA-XR alone. HA + Col F hydrogel had a much greater effect on release rates of 70 kDa compared to 4 kDa dextran, while Col F incorporated into the HA-XR hydrogel accentuated differences in release rates of prandial and basal forms of insulin as well as decreased the release rate of denosumab. A hydrogel format of HA + Col I was used to examine the complex events for bevacizumab release under conditions where a target ligand (vascular endothelial growth factor) can interact with extracellular matrix (ECM). Together, these data have demonstrated the feasibility of using a cross-linked HA format to examine API release over multiple days and incorporation of specific ECM elements to prepare more biomimetic hydrogels that allow for tractable examination of their potential impact of API release.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hyaluronic AcidHydrogelsInjections, SubcutaneousHumansAnimalsDrug InteractionsCattleRheologyChondroitin SulfatesInsulinBevacizumabCollagen

Stichwörter der Autor:innen

Drug fateExtracellular matrixIn vitro modelSubcutaneous injection

Substanzen

Hyaluronic AcidHydrogelsChondroitin SulfatesInsulinBevacizumabCollagen

Autor:innen und Institutionen

  • Pion, Inc., Billerica, MA 01821, USA.
  • Department of Life Sciences, Centre for Therapeutic Innovation, University of Bath, Bath BA2 7AY, UK.
  • Department of Life Sciences, Centre for Therapeutic Innovation, University of Bath, Bath BA2 7AY, UK. Electronic address: Rjm37@bath.ac.uk.

Zitieren

APA

Gomes, C., Gridley, K., Anastasiou, I., Sinkó, B., & Mrsny, R. J. (2024). Hydrogel formats to model potential drug interactions occurring at the subcutaneous injection site. European Journal of Pharmaceutics and Biopharmaceutics, 199, 114308. https://doi.org/10.1016/j.ejpb.2024.114308

Vancouver

Gomes C, Gridley K, Anastasiou I, Sinkó B, Mrsny RJ. Hydrogel formats to model potential drug interactions occurring at the subcutaneous injection site. European Journal of Pharmaceutics and Biopharmaceutics. 2024;199:114308. doi:10.1016/j.ejpb.2024.114308

BibTeX
@article{Gomes2024,
  author = {Gomes, Conor and Gridley, Kate and Anastasiou, Imogen and Sinkó, Bálint and Mrsny, Randall J},
  title = {Hydrogel formats to model potential drug interactions occurring at the subcutaneous injection site},
  journal = {European Journal of Pharmaceutics and Biopharmaceutics},
  year = {2024},
  volume = {199},
  pages = {114308},
  doi = {10.1016/j.ejpb.2024.114308}
}
Kostenlos starten →